Trials: Type IIa and IIb Hypercholesterolaemia

Phase 4 N=140 Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

Non ST Elevation Myocardial Infarction

Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) — 35.3; 13.8 Percentage of study group

Medical University of Silesia Results Oct 2013 6.4% serious AE View details

Phase 3 N=315 An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

Familial Hypercholesterolaemia

Primary: Percent Change From Baseline in LDL-C — -37.86; -43.67; -42.88 Percentage change — p=<0.001

AstraZeneca Results Feb 2015 4.6% serious AE View details

Phase 2 N=884 A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

Pneumococcal Infection

Primary: Number of Participants Reporting Solicited Local and Systemic Adverse Events — 148; 153; 187; 213 participants

National Institute of Allergy and Infectious… Results Jan 2017 2.8% serious AE View details

N/A N=5 Proton Radiotherapy for Stage I, IIA, and IIB Seminoma

Stage I, IIA and IIB Seminoma

Primary: Number of Serious Adverse Events — 0 Participants

Abramson Cancer Center at Penn Medicine Results Nov 2019 0.0% serious AE View details

Phase 1 N=24 Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State

Malaria

Primary: OZ439 Cmax — 1540; 1360; 1610 ng/mL

Medicines for Malaria Venture Results Apr 2015 0.0% serious AE View details

N/A N=30 Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer

Breast Cancer

Primary: Acute Radiation Effects (Less Than 90 Days Post Treatment) — 0 Participants

Ottawa Hospital Research Institute Results Jun 2025 16.7% serious AE View details

Phase 2 N=70 NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients

Cystic Fibrosis

Primary: Change in the Logarithm of the Level of Human Neutrophil Elastase (HNE) Activity Measured in Sputum — 0.03; -0.17 log10 mcg/mL — p=0.14

Stanford University Results Mar 2013 45.7% serious AE View details

Phase 2 N=175 Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia

Leukemia, Myeloid, Acute

Primary: Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B) — 350; 450 milligram (mg)

Boehringer Ingelheim Results Oct 2023 70.3% serious AE View details

Phase 2 N=353 Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

Diabetes Mellitus

Primary: Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. — 1.016; 0.955; 0.874 mg/g

AstraZeneca Results Dec 2010 16.9% serious AE View details

Phase 2 N=275 Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH)

Primary: Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) — 21…

Genfit Results Nov 2022 12.8% serious AE View details

Phase 3 N=1,220 To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Hypercholesterolemia

Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) — -20.1; -58.5 Percent change — p=<0.001

Organon and Co Results Aug 2009 View details

Phase 2 N=237 Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

Hyperlipidemia

Primary: Urinary Protein/Creatinine Ratio at Week 52 [LOCF] — 0.938; 1.082; 0.759 ratio

AstraZeneca Results Dec 2010 8.9% serious AE View details

Phase 3 N=46 Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Homozygous Familial Hypercholesterolaemia (HoFH)

Primary: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline — -53.910; -56.529; -51.633 Percent change from Baseline…

Amryt Pharma Results Aug 2025 25.6% serious AE View details

Phase 3 N=833 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

Hypercholesterolemia · Coronary Heart Disease · Atherosclerosis

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment — -59.7200; -63.4800; -55.2200; -57.4200 Percentage

AstraZeneca Results Oct 2009 View details

Phase 2 N=309 A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Infection, Human Immunodeficiency Virus · HIV Infections

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Level Below 50 Copies/Milliliter (c/mL) at Week 32 — 95; 94; 91…

ViiV Healthcare Results Aug 2020 14.1% serious AE View details

Clinical Trial Search